pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 15·1 min read
save

Johnson & Johnson to spend up to $750 million restructuring pharma manufacturing and closing plants

Jul 15, 2026·read at Endpoints ↗Neutral

Johnson & Johnson announced it will incur up to $750 million as it reshapes its pharmaceutical manufacturing network.

The plan involves exiting certain factories and consolidating production, aiming to streamline the supply chain.

The restructuring is part of the company's broader $55 billion commitment to transform its business, though the exact timeline and locations were not disclosed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “J&J restructures pharma manufacturing footprint at cost of up to $750M”

read at Endpoints ↗
82 words · retrieved Jul 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
JOHNSON & JOHNSON2

related stories

  • Jun 8J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldEndpoints
  • Jun 8STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and moreSTAT
  • Jun 8STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsSTAT
  • Jun 4Parabilis Medicines charts $413M IPO to back peptide pipelineEndpoints
  • Jun 3Legend surges on early data for ‘in vivo’ lymphoma cell therapyBioPharma Dive